This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDelta 9 Cannabis（V5D1）株式概要Delta 9 Cannabis Inc.は、その子会社とともに総合大麻企業として運営している。 詳細V5D1 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より97.9%で取引されている リスク分析マイナスの株主資本 株式の流動性は非常に低い 過去5年間で収益は年間51.6%減少しました。 過去1年間で株主の希薄化は大幅に進んだ +1 さらなるリスクすべてのリスクチェックを見るV5D1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,210 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,210 investors already sharing narrativesYour Fair Value€Current Price€0.007295.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-26m177m2016201920222025202620282031Revenue CA$176.7mEarnings CA$25.7mAdvancedSet Fair ValueView all narrativesDelta 9 Cannabis Inc. 競合他社BiofronteraSymbol: XTRA:B8FKMarket cap: €14.7mSynBioticSymbol: DUSE:SBXMarket cap: €8.1mCantourage GroupSymbol: XTRA:HIGHMarket cap: €73.3mRedx PharmaSymbol: DB:0RXMarket cap: €65.0m価格と性能株価の高値、安値、推移の概要Delta 9 Cannabis過去の株価現在の株価US$0.007252週高値US$0.07852週安値US$0.0062ベータ1.311ヶ月の変化0%3ヶ月変化-2.70%1年変化-80.75%3年間の変化-97.37%5年間の変化n/aIPOからの変化-99.70%最新ニュースお知らせ • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).お知らせ • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023最新情報をもっと見るRecent updatesお知らせ • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).お知らせ • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023New Risk • Jul 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €151k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Shares are highly illiquid. Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (€6.62m market cap, or US$7.36m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (€151k sold).お知らせ • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023お知らせ • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 04Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.Board Change • Apr 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 28Co-Founder recently sold €93k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly €0.35 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €121k.Recent Insider Transactions • May 22Co-Founder recently sold €78k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly €0.34 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €206k.Reported Earnings • May 18First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 04Full year 2020 earnings released: CA$0.072 loss per share (vs CA$0.13 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 159% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 29New 90-day low: €0.30The company is down 17% from its price of €0.37 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.16 per share.Recent Insider Transactions • Dec 24Co-Founder recently bought €62k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly €0.35 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €206k.Is New 90 Day High Low • Dec 22New 90-day low: €0.33The company is down 7.0% from its price of €0.36 on 22 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.37 per share.Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Oct 14Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, VIGR Life Cannabis Inc. (“VIGR”). As one of Delta 9’s Micro Cultivation partners, VIGR entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the VIGR brand and other services supporting the acquisition of the Health Canada license. On October 2, 2020, VIGR confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). VIGR has developed a micro cultivation facility, located in Regina, Saskatchewan. This new facility houses two adjacent micro cultivation licenses, including twenty-four new Grow Pod systems, and a proprietary craft growing approach developed by VIGR. VIGR expects this first facility to be the first step in a more significant growth plan, as it builds Saskatchewan’s leading craft cannabis company.お知らせ • Oct 01Delta 9 Cannabis Inc. to Report Q2, 2019 Results on Aug 27, 2019Delta 9 Cannabis Inc. announced that they will report Q2, 2019 results at 5:00 PM, Eastern Standard Time on Aug 27, 2019お知らせ • Sep 30Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC. announced that it has completed its final services milestone under an agreement with another Micro Cultivation partner, Prairie Trichomes. Prairie Trichomes is an arms length third party in which the company has no ownership control or interest. As one of the company’s Micro Cultivation partners, Prairie Trichomes entered into a Strategic Cooperation Agreement with Delta 9 whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On September 18, 2020, Prairie Trichomes confirmed it had reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Prairie Trichomes’ facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Prairie Trichomes for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Prairie Trichomes operates a 4th generation farm and has developed a 6,000 square foot micro cultivation facility, located in Carberry, Manitoba. The warehouse is only half utilized with the twelve new grow pods in place which provides room for expansion. The Carritt Family are experienced farmers who are excited to be a part of a new and growing industry. They became interested in growing cannabis to produce a premium cannabis crop year-round and provide additional jobs in rural Manitoba.お知らせ • Jul 31Delta 9 Cannabis Inc. to Report Q2, 2020 Results on Aug 14, 2020Delta 9 Cannabis Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020お知らせ • Jun 16Delta 9 Cannabis Inc. (TSX:DN) entered into an agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini.Delta 9 Cannabis Inc. (TSX:DN) entered into a definitive agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini on June 15, 2020. As part of consideration, Oceanic will be paid by way of the provision of certain consulting and training services to Oceanic over a term of one year pursuant to a strategic cooperation agreement. The transaction is subject to obtaining of all required third party and governmental consents, authorizations and licenses required in connection therewith, including without limitation all required authorizations from Labrador Liquor Corporation.株主還元V5D1DE PharmaceuticalsDE 市場7D0%-2.3%-2.3%1Y-80.7%45.7%0.3%株主還元を見る業界別リターン: V5D1過去 1 年間で45.7 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: V5D1は、過去 1 年間で0.3 % のリターンを上げたGerman市場を下回りました。価格変動Is V5D1's price volatile compared to industry and market?V5D1 volatilityV5D1 Average Weekly Movementn/aPharmaceuticals Industry Average Movement5.8%Market Average Movement5.4%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.8%安定した株価: V5D1の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のV5D1のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001320John Arbuthnotwww.delta9.caDelta 9 Cannabis Inc.は、その子会社とともに総合大麻企業として事業を展開している。同社は、医療用および娯楽用大麻製品の栽培、加工、抽出、卸売、小売、販売に従事している。同社の製品には、乾燥大麻の花、プリロール、乾燥ふるい大麻のほか、オイル、抽出・派生製品がある。同社はまた、栽培ポッドや生きた植物を他のライセンス企業やプレライセンス企業に提供している。さらに、大麻処方のための医療推薦を求める患者に医師の相談サービスを提供する医療クリニックとしても運営している。同社はカナダの各州で「デルタ9」のブランド名で小売店を運営している。また、オーストラリアにも製品を輸出している。同社は2001年に法人化され、カナダのバンクーバーを拠点としている。もっと見るDelta 9 Cannabis Inc. 基礎のまとめDelta 9 Cannabis の収益と売上を時価総額と比較するとどうか。V5D1 基礎統計学時価総額€2.50m収益（TTM）-€13.11m売上高(TTM)€47.25m0.1xP/Sレシオ-0.2xPER（株価収益率V5D1 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計V5D1 損益計算書（TTM）収益CA$70.65m売上原価CA$58.10m売上総利益CA$12.55mその他の費用CA$32.15m収益-CA$19.60m直近の収益報告Mar 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.054グロス・マージン17.77%純利益率-27.74%有利子負債／自己資本比率-447.3%V5D1 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/03 05:42終値2024/07/16 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Delta 9 Cannabis Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kimberly Thompson-HedlinCanaccord GenuitySiddharth RajeevFundamental Research Corp.Venkata VelagapudiResearch Capital Corporation
お知らせ • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).
お知らせ • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
お知らせ • Jul 16FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN).FIKA entered into a binding term sheet agreement to acquire Cannabis retail store business and the logistics and distribution business of Delta 9 Cannabis Inc. (TSX:DN) on July 15, 2024. MLT Aikins LLP acted as legal advisor to Delta 9 Cannabis Inc.
Reported Earnings • May 17First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.02 loss in 1Q 2023)First quarter 2024 results: CA$0.02 loss per share (in line with 1Q 2023). Revenue: CA$16.5m (down 2.4% from 1Q 2023). Net loss: CA$5.07m (loss widened 70% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Apr 20Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024.
Reported Earnings • Apr 02Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)Full year 2023 results: CA$0.10 loss per share (improved from CA$0.22 loss in FY 2022). Revenue: CA$71.1m (up 12% from FY 2022). Net loss: CA$17.5m (loss narrowed 36% from FY 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
New Risk • Feb 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$606k). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (€3.09m market cap, or US$3.31m).
お知らせ • Oct 31Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023Delta 9 Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)Second quarter 2023 results: CA$0.02 loss per share (improved from CA$0.04 loss in 2Q 2022). Revenue: CA$18.3m (up 4.3% from 2Q 2022). Net loss: CA$2.82m (loss narrowed 41% from 2Q 2022). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 28Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023Delta 9 Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
New Risk • Jul 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €151k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Shares are highly illiquid. Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (€6.62m market cap, or US$7.36m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (€151k sold).
お知らせ • May 09+ 1 more updateDelta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023Delta 9 Cannabis Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023
お知らせ • Jan 19+ 1 more updateDelta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023Delta 9 Cannabis Inc. announced that they will report Q4, 2022 results on Mar 31, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.06 loss per share (further deteriorated from CA$0.011 loss in 3Q 2021). Revenue: CA$15.7m (up 3.3% from 3Q 2021). Net loss: CA$7.40m (loss widened CA$6.28m from 3Q 2021). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 16First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)First quarter 2022 results: CA$0.04 loss per share (up from CA$0.042 loss in 1Q 2021). Revenue: CA$12.5m (down 5.7% from 1Q 2021). Net loss: CA$4.17m (loss narrowed 2.8% from 1Q 2021). Over the next year, revenue is forecast to grow 49%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Board Change • May 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 04Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)Full year 2021 results: CA$0.11 loss per share (down from CA$0.072 loss in FY 2020). Revenue: CA$62.3m (up 20% from FY 2020). Net loss: CA$11.2m (loss widened 74% from FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.
Board Change • Apr 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Hugh Aird was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 28Co-Founder recently sold €93k worth of stockOn the 26th of May, John Arbuthnot sold around 270k shares on-market at roughly €0.35 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €121k.
Recent Insider Transactions • May 22Co-Founder recently sold €78k worth of stockOn the 18th of May, John Arbuthnot sold around 230k shares on-market at roughly €0.34 per share. This was the largest sale by an insider in the last 3 months. John has been a seller over the last 12 months, reducing personal holdings by €206k.
Reported Earnings • May 18First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$13.2m (up 13% from 1Q 2020). Net loss: CA$4.29m (down 309% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 04Full year 2020 earnings released: CA$0.072 loss per share (vs CA$0.13 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$52.0m (up 64% from FY 2019). Net loss: CA$6.42m (down 159% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 29New 90-day low: €0.30The company is down 17% from its price of €0.37 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.16 per share.
Recent Insider Transactions • Dec 24Co-Founder recently bought €62k worth of stockOn the 21st of December, John Arbuthnot bought around 176k shares on-market at roughly €0.35 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €206k.
Is New 90 Day High Low • Dec 22New 90-day low: €0.33The company is down 7.0% from its price of €0.36 on 22 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.37 per share.
Reported Earnings • Nov 13Third quarter 2020 earnings released: CA$0.07 loss per shareThe company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$13.1m (up 97% from 3Q 2019). Net loss: CA$5.85m (loss widened 307% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Oct 14Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDelta 9 Cannabis Inc. announced that it has completed its final services milestone under an agreement with Saskatchewan based Micro Cultivation partner, VIGR Life Cannabis Inc. (“VIGR”). As one of Delta 9’s Micro Cultivation partners, VIGR entered into a Strategic Cooperation Agreement (“SCA”) with the company whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, marketing services to develop the VIGR brand and other services supporting the acquisition of the Health Canada license. On October 2, 2020, VIGR confirmed it had reached its final milestone under the SCA and has been granted its cannabis micro cultivation licenses from Health Canada (the “Health Canada License”). VIGR has developed a micro cultivation facility, located in Regina, Saskatchewan. This new facility houses two adjacent micro cultivation licenses, including twenty-four new Grow Pod systems, and a proprietary craft growing approach developed by VIGR. VIGR expects this first facility to be the first step in a more significant growth plan, as it builds Saskatchewan’s leading craft cannabis company.
お知らせ • Oct 01Delta 9 Cannabis Inc. to Report Q2, 2019 Results on Aug 27, 2019Delta 9 Cannabis Inc. announced that they will report Q2, 2019 results at 5:00 PM, Eastern Standard Time on Aug 27, 2019
お知らせ • Sep 30Delta 9 Cannabis Inc. Achieves Milestone in Agreement with Micro Cultivation PartnerDELTA 9 CANNABIS INC. announced that it has completed its final services milestone under an agreement with another Micro Cultivation partner, Prairie Trichomes. Prairie Trichomes is an arms length third party in which the company has no ownership control or interest. As one of the company’s Micro Cultivation partners, Prairie Trichomes entered into a Strategic Cooperation Agreement with Delta 9 whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license. On September 18, 2020, Prairie Trichomes confirmed it had reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the “Health Canada License”). The company's cannabis production methodology is based around a modular, scalable, and stackable production unit called a "Grow Pod", which are retrofitted standard 40-foot shipping containers. Prairie Trichomes’ facility has been designed and built using this turn key and Grow Pod system. Once cultivation begins, Delta 9 plans to purchase premium quality cannabis products from Prairie Trichomes for distribution through the Company's established distribution network, and through Delta 9's branded retail stores. Prairie Trichomes operates a 4th generation farm and has developed a 6,000 square foot micro cultivation facility, located in Carberry, Manitoba. The warehouse is only half utilized with the twelve new grow pods in place which provides room for expansion. The Carritt Family are experienced farmers who are excited to be a part of a new and growing industry. They became interested in growing cannabis to produce a premium cannabis crop year-round and provide additional jobs in rural Manitoba.
お知らせ • Jul 31Delta 9 Cannabis Inc. to Report Q2, 2020 Results on Aug 14, 2020Delta 9 Cannabis Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020
お知らせ • Jun 16Delta 9 Cannabis Inc. (TSX:DN) entered into an agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini.Delta 9 Cannabis Inc. (TSX:DN) entered into a definitive agreement to acquire a 5% stake in Oceanic Releaf Inc. from Taylor Giovannini on June 15, 2020. As part of consideration, Oceanic will be paid by way of the provision of certain consulting and training services to Oceanic over a term of one year pursuant to a strategic cooperation agreement. The transaction is subject to obtaining of all required third party and governmental consents, authorizations and licenses required in connection therewith, including without limitation all required authorizations from Labrador Liquor Corporation.
